Abivax Completes $747.5 Million Public Offering

On July 28, 2025, French biotechnology company Abivax announced the completion of a public offering in the United States. This offering includes 11,679,400 American Depositary Shares (ADSs), representing the company's ordinary shares. The total amount raised is $747.5 million, or approximately €637.5 million, after the full exercise of the over-allotment option.

The estimated net proceeds of $700.3 million are expected to support Abivax's operations through 2027. This includes funding for the submission for regulatory approval of its treatment for ulcerative colitis. The ADSs are listed on the Nasdaq under the symbol "ABVX."

The principal financial institutions involved in this offering are Leerink Partners, Piper Sandler & Co., and Guggenheim Securities. Their combined efforts are aimed at supporting Abivax's financial and clinical strategy in the North American market.